Vericel (VCEL)
(Delayed Data from NSDQ)
$46.57 USD
-1.46 (-3.04%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $46.55 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Vericel Corporation [VCEL]
Reports for Purchase
Showing records 1 - 20 ( 44 total )
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Another Strong Quarter with Catalysts Expected in 2H24; New $60 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
A Strong Start To the Year; New PT $55; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Arthroscopic MACI to Deepen Addressable Market; New PT $53; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Expecting Growth Inflection from New Products; New $46 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for VCEL 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
MACI Indication Expansion and NexoBrid to Fuel Growth in 2024 and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
NexoBrid Launch to Strengthen Burn Care Franchise; New PT $44.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
MACI Indication Expansions to Deliver Sustainable Growth; New PT $41; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
2023 Shaping Up to Be Another Year of Strong Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Looking Ahead to New Product Launches; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
MACI Delivers Again; Growth to Continue in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
NexoBrid Receives FDA Approval; Raise PT to $37; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Remain Confident in MACI Long-Term Growth Albeit Near-Term Weakness; Lower PT to $35; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
2022 Revenues Poised for Growth in 2H22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Epicel Punches in Strong; Overall Growth Momentum Expected in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Strong Growth Continues, Adjusting PT to $53; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S